semaglutide and kidney disease in patients with overweight or obesity chronic without diabetes: a randomized double-blind placebo-controlled clinical trial Evolution of CKD risk after

Fertility and Sterility , 81(6), 1578-1584

The researchers found that patients taking GLP-1RAs had a 78% lower risk of death and a 44% lower risk of major cardiovascular events compared to those taking other weight loss medications

In other words, GLP-1 medications are not being studied as hormone therapy

This research shows that alpha cells are more flexible than we imagined, said lead author of the study, Jonathan Campbell, PhD, associate professor in the division of endocrinology in the department of medicine at Duke University and a member of the Duke Molecular Physiology Institute

Front Immunol 12:770744 Arensdorf AM, Marada S, Ogden SK (2016) Smoothened regulation: a tale of two signals